RetailUSLiteBud pre-roll hopes to cash in on success of light beer market

Vireo’s new brand takes a not-so-subtle cue from America’s most popular beer
Nick Laba Nick LabaJanuary 6, 20206 min

A new brand of pre-rolled cannabis is trying to cash in on the success of America’s most popular beer, with its cannily named LiteBud.

U.S.-based producer Vireo Health International, Inc. (CNSX: VREO and OTCQX: VREOF) has taken a cue from by far beer’s most profitable market segment: light beer.

America’s two most popular brands of beer, Bud Light and Coors Light, are of the low-alcohol variety, according to data from Beer Marketer’s Insights. While sales have slowed in recent years, Bud Light still commands around a 14 per cent market share.

Vireo’s head of marketing, Harris Rabin, said LiteBud’s branding is informed by the tailgate-friendly beer business.

LiteBud pre-rolled cannabis
As you might have guessed by the name, LiteBud is targeting consumers looking for smaller doses of psychoactive ingredients. Photo courtesy of Vireo

“As the U.S. cannabis market matures and serves a broader segment of the adult population, we believe that there will be a significant consumer demand for low-THC products,” he said.

Specifically, the pre-rolls are designed to meet the needs of consumers seeking a more consistent, controlled and mild experience, the company said in a press release Monday.

Stock in Vireo has been steadily rising since mid-December, and was up 6.25 per cent on the day to $1.53 a share.

Vireo’s strategy goes in the opposite direction from the overall industry trend of growing more and more potent strains. Companies like The Green Organic Dutchman (TSE: TGOD) and Rubicon Organics (CSE: ROMJ) cite evidence there’s demand for more super premium cannabis.

But LiteBud is aiming low, at least in terms of THC content — from four to 10 per cent.

Read more: Rubicon Organics signs distribution deal for new premium weed, acquires new genetics

In the press release, Vireo references research from the University of Mississippi showing the sharp upward trend in THC concentration over the years. In 1995, average potency was around 4 per cent, increasing to 9 per cent in 2008 and to 17 per cent in 2017.

Today, most flower available in medical and recreational markets is cultivated to maximize potency, and sophisticated techniques often yield THC levels exceeding 25 per cent, Vireo says.

‘This is your father’s cannabis’

There are low-THC products available on the Canadian market, including the Harlequin grown by Tantalus Labs. However, most of those strains are marketed toward consumers looking for weed higher in CBD, not those in search of a chill buzz.

“Vireo is committed to creating innovative products that reflect the needs of all cannabis consumers,” CEO Kyle Kingsley said in the release. “LiteBud offers patients a lower-THC product line with carefully controlled cannabinoid levels to help prevent the unpleasant side effects many experience with high-THC products.”

“In a sense, this is your father’s cannabis since its cannabinoid levels are more reminiscent of the type of flower that was widely used a generation or two ago,” Kingsley said.

LiteBud is currently available at cannabis stores in the state of Maryland, and the company said it has plans to expand to its other markets later this year.

Vireo is licenced in 11 states including Arizona, Maryland, Massachusetts, Minnesota, New Mexico, New York, Nevada, Ohio, Pennsylvania, Puerto Rico, and Rhode Island, according to its website.

 

nick@mugglehead.com

@nick_laba

Leave a Reply

Your email address will not be published. Required fields are marked *